Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Famotidine on Taletrectinib PK in Healthy Adults
NCT07742384Phase 1Not yet recruiting
- Sponsor
- Nuvation Bio
- Start
- Aug 2026
- Primary completion
- Feb 2027
01
Overview
Phase 1, open-label trial of taletrectinib (6 arms), sponsored by Nuvation Bio. Primary endpoints: Maximum Observed Plasma Concentration at Day 30, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at Day 30 and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
taletrectinib
Beyond the preview
Go deeper on NCT07742384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07742384.